← Back to patent-cliff list
HL-300
Tier C — Watch / tradeHL-300
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TYK2, JAK2, JAK1
Indications (approved)：Atopic dermatitis, Eczema, Plaque psoriasis
Regional status
US
-
EU
-
China
Phase II
2026-05-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HL-300?
Approved indications include: Atopic dermatitis, Eczema, Plaque psoriasis.
When does the HL-300 patent expire?
No public expiry year is available for HL-300 yet; this page updates once verified.
How do I get a quote for HL-300 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29